Feasibility of the inhibitor development for cancer: A systematic approach for drug design
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306632 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yu Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu,…. Hauptthemen laut MEDLINE: Quercetin, STAT3 Transcription Factor, Molecular Docking Simulation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Sichuan Province Science and Technology Support Program.
Abstract (Originalsprache)
The traditional Chinese medicine (TCM) bupleurum-ginger-licorice formula presents significant anti-cancer effects, but its active ingredients and inhibitory mechanism remain unclear. In this work, the core effective ingredient quercetin and its signal transducer and activator of transcription 3 (Stat3) receptor both were identified by network pharmacology. Quercetin is a low-toxicity, non-carcinogenic flavonoid with antioxidant, anti-inflammatory and anticancer activities, which is widely distributed in edible plants. Stat3 can bind to specific DNA response elements and serves as a transcription factor to promote the translation of some invasion/migration-related target genes, considered as a potential anticancer target. Here, molecular docking and molecular dynamics (MD) simulation both were used to explore molecular recognition of quercetin with Stat3. The results show that quercetin impairs DNA transcription efficiency by hindering Stat3 dimerization, partially destroying DNA conformation. Specifically, when the ligand occupies the SH2 cavity of the enzyme, spatial rejection is not conductive to phosphokinase binding. It indirectly prevents the phosphorylation of Y705 and the formation of Stat3 dimer. When the inhibitor binds to the DT1005 position, it obviously shortens the distance between DNA and DBD, enhances their binding capacity, and thereby reduces the degree of freedom required for transcription. This work not only provides the binding modes between Stat3 and quercetin, but also contributes to the optimization and design of such anti-cancer inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medicinal and Edible Plants Resources Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, China.
- Department of Thoracic Oncology, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China.
ORCID-Profile: Weiwei Ouyang, Jianping Hu
Förderung
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Jiang, Y., Liu, L., Geng, Y., Li, Q., Luo, D., Liang, L., Liu, W., Ouyang, W., & Hu, J. (2024). Feasibility of the inhibitor development for cancer: A systematic approach for drug design. PLOS ONE. https://doi.org/10.1371/journal.pone.0306632
Vancouver
Jiang Y, Liu L, Geng Y, Li Q, Luo D, Liang L, et al. Feasibility of the inhibitor development for cancer: A systematic approach for drug design. PLOS ONE. 2024. doi:10.1371/journal.pone.0306632
BibTeX
@article{Jiang2024,
author = {Jiang, Yu and Liu, Ling and Geng, Yichao and Li, Qingsong and Luo, Daxian and Liang, Li and Liu, Wei and Ouyang, Weiwei and Hu, Jianping},
title = {Feasibility of the inhibitor development for cancer: A systematic approach for drug design},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306632}
}
EUVIMED